iShares Biotechnology ETF
IBB
IBB
431 hedge funds and large institutions have $6B invested in iShares Biotechnology ETF in 2015 Q4 according to their latest regulatory filings, with 78 funds opening new positions, 130 increasing their positions, 152 reducing their positions, and 57 closing their positions.
Holders
431
Holders Change
+17
Holders Change %
+4.11%
% of All Funds
11.32%
Holding in Top 10
32
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+10.34%
% of All Funds
0.84%
New
78
Increased
130
Reduced
152
Closed
57
Calls
$795M
Puts
$1.37B
Net Calls
-$571M
Net Calls Change
+$30.9M
Top Buyers
Top Sellers
| 1 |
CS
1
Credit Suisse
Zurich,
Switzerland
|
$11.9M |
| 2 |
2
Morgan Stanley
New York
|
$622M |
| 3 |
3
Citigroup
New York
|
$401M |
| 4 |
4
Goldman Sachs
New York
|
$894M |
| 5 |
5
JPMorgan Chase & Co
New York
|
$242M |
| Name | Market Value | Shares |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
BA
501
BlackRock Advisors
Wilmington,
Delaware
| – | – | – | – |
|
502
Public Sector Pension Investment Board (PSP Investments)
Montreal,
Quebec, Canada
| – | – | – | – |
|
|
JT
503
Jump Trading
Chicago,
Illinois
| – | – | – | – |
|
|
SPM
504
Symmetry Peak Management
Radnor,
Pennsylvania
| – | – | – | – |
|
|
KCM
505
Kingdon Capital Management
New York
| – | – | – | – |
|
|
SAM
506
Serengeti Asset Management
New York
| – | – | – | – |
|
|
HT
507
HAP Trading
New York
| – | – | – | – |
|
|
ID
508
Integral Derivatives
New York
| – | – | – | – |
|
|
ICM
509
Ionic Capital Management
New York
| – | – | – | – |
|
|
AG
510
Artal Group
Luxembourg
| – | – | – | – |
|